Dark

ACIU
AC Immune SA
stock NASDAQ

At Close

Jul 28, 2026 3:59:57 PM EDT

2.32USD+0.652%(+0.02)104,137

2.31Bid 2.32Ask 0.01Spread

Pre-market

Jul 27, 2026 9:27:30 AM EDT

2.23USD0.000%(0.00)0

After-hours

Jul 27, 2026 4:13:30 PM EDT

2.30USD-0.433%(-0.01)0

OverviewOptionsHistoricalExchangesShortsNews

Dec 20, 2021

04:47AM EST SVB Leerink Maintains Outperform on AC Immune, Lowers Price Target to $15 Benzinga

Dec 15, 2021

07:52AM EST AC Immune Awarded Two Michael J. Fox Foundation Grants To Advance Small Molecule Parkinson's Disease Programs; Size Not Disclosed Benzinga

07:50AM EST Funding to accelerate the development of first-in-class brain penetrant small molecules to inhibit a-syn aggregation and NLRP3 inflammasome activation in Parkinsons disease (PD) GlobeNewswire Inc

Nov 12, 2021

11:58AM EST AC Immune shares were trading higher after the company announced interim Phase 1b/2a data showing that its AACI-35.030 anti-pTau Alzheimer's vaccine generated a 'potent immune response.' Benzinga

08:27AM EST AC Immune Announces Interim Phase 1b/2a Data Showing That Its ACI-35.030 Anti-pTau Alzheimer's Vaccine Generates A 'Potent Immune Response' Benzinga

08:22AM EST Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment GlobeNewswire Inc

Nov 10, 2021

11:21AM EST AC Immune Announces Late-Breaker Presentation By Genentech At CTAD On Phase 2 Lauriet Study Of Semorinemab In Mild-To-Moderate Alzheimer's Disease Benzinga

11:20AM EST Analysis of the broader mITT population is consistent with the previously reported success in meeting one of the two co-primary endpoints (ADAS-Cog11) with statistically significant reduction in the rate of cognitive decline vs. placebo GlobeNewswire Inc

08:23AM EST The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance Benzinga

Nov 9, 2021

11:42AM EST The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Benzinga

Nov 8, 2021

08:29AM EST The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Benzinga

07:09AM EST AC Immune Q3 EPS $(0.22) Up From $(0.26) YoY Benzinga

07:00AM EST Announced the first positive cognitive results for a Tau-targeting monoclonal antibody in mild-to-moderate Alzheimers disease GlobeNewswire Inc

05:51AM EST Shares of Alzheimer's Drug Stocks AC Immune, Galamed Pharma, Annovis Bio Higher After Comments by AC Immune CEO on Sunday that Number of Alzheimer's Cases Could Triple by 2050 Benzinga

05:50AM EST Shares of Alzheimer's Drug Stocks AC Immune, Galamed Pharma, Annovis Bio Higher After Comments by AC Immune CEO on Sunday Benzinga

Nov 4, 2021

06:00AM EDT AC Immune Extends Research Collaboration with University of GlobeNewswire Inc

Nov 2, 2021

10:52AM EDT AC Immune Highlights New Data On Investigational Alzheimer's Disease Candidates Will Be Featured In Scientific Program Of 'Clinical Trials On Alzheimer's Disease' Conference Nov. 9-12, 2021 Benzinga

07:30AM EDT New Data on AC Immunes Abeta and pTau Clinical GlobeNewswire Inc

Oct 29, 2021

06:00AM EDT Dr. Shaw is a pharmaceutical industry expert who has been involved in advancing more than 15 therapeutic products from first-in-human studies through commercialization GlobeNewswire Inc

Oct 25, 2021

07:00AM EDT AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company management will participate in a fireside chat and one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 2021. GlobeNewswire Inc

Oct 14, 2021

07:28AM EDT AC Immune S.A.Genentech, Inc. Filed U.S. Patent Application 'HUMANIZED ANTIBODY' Benzinga

Oct 7, 2021

01:33PM EDT AC Immune Granted Australian Patent Titled '1, 3, 4, 5-tetrahydro-2H-pyrido(4,3-b)indole derivatives for the treatment, alleviation or prevention of disorders associated with Tau aggregates like Alzheimer's disease' Benzinga

Sep 21, 2021

07:37AM EDT AC Immune and Janssen Pharmaceuticals Granted U.S. Patent #11,124,552 'Compositions of phosphorylated tau peptides and uses thereof' Benzinga

07:37AM EDT AC Immune and Janssen Pharmaceuticals Granted U.S. Patent 'Compositions of phosphorylated tau peptides and uses thereof' Benzinga

Sep 3, 2021

07:53AM EDT AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced its Co-Founder and CEO Andrea Pfeifer has been awarded by the Swiss Economic Forum (SEF) with the SEF.WomenAward, in the category CEO of the Year, during a ceremony at the SEF meeting in Interlaken on September 2, 2021. GlobeNewswire Inc

Sep 2, 2021

09:45AM EDT AC Immune Files For U.S. Patent Titled 'Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates' Benzinga

07:00AM EDT AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in the following upcoming virtual investor conferences: GlobeNewswire Inc

Sep 1, 2021

07:32AM EDT The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering Benzinga

Aug 31, 2021

02:26PM EDT Mid-Afternoon Market Update: Spok Holdings Surges On Takeover Offer; Sequential Brands Shares Slide Benzinga

02:03PM EDT Mid-Morning Market Update: Markets Edge Lower; Designer Brands Earnings Top Estimates Benzinga

12:13PM EDT Mid-Day Market Update: Zoom Shares Drop After Q2 Results; AC Immune Shares Surge Benzinga

10:22AM EDT Mid-Morning Market Update: Markets Edge Lower; Designer Brands Earnings Top Estimates Benzinga

10:10AM EDT Shares of AC Immune SA (ACIU) are surging over 70% on Tuesday morning after the Swiss clinical-stage biopharmaceutical company announced positive results from mid-stage trial in older patients with early Alzheimer's disease. RTTNews

07:32AM EDT AC Immune Announces Top-Line Data From Lauriet Phase 2 Trial Of Semorinemab 'shows a statistically significant reduction on one of two co-primary endpoints, ADAS-Cog11' Benzinga

07:30AM EDT Top-line data from Lauriet Phase 2 trial of semorinemab in mild-to-moderate AD shows a statistically significant reduction on one of two co-primary endpoints, ADAS-Cog11 GlobeNewswire Inc

Aug 4, 2021

07:19AM EDT AC Immune Q2 2021 EPS CHF(0.26), Down From CHF(0.22) YoY Benzinga

07:00AM EDT Announced strategic acquisition of industry-leading Parkinsons disease vaccine and equity investment led by key investors in Covid-19 vaccine innovator BioNTech SE GlobeNewswire Inc

Jul 29, 2021

07:53AM EDT AC Immune Highlights Presentation Of Phase 1b Results On Anti-Abeta Vaccine, Discusses Diagnostic For Parkinson's Disease at Alzheimer's Association International Conference Benzinga

07:30AM EDT ACI-24 generated an encouraging immune response that correlated with a signal of target engagement in patients with Down syndrome (DS) GlobeNewswire Inc

Jul 27, 2021

11:13AM EDT AC Immune shares were trading higher after the company announced the strategic acquisition of industry-leading Parkinson's disease vaccine candidate and equity investment led by Athos Service GmbH. Benzinga

11:13AM EDT AC Immune Secures Funding From BioNTech Investors, Buys Parkinson's Vaccine Candidate Benzinga

11:13AM EDT AC Immune Acquires AFFiRiS' Specific Active Immunotherapy Anti-Alpha-Synuclein Programs Targeting Neurodegenerative Diseases For $58.7M In Stock Benzinga

11:13AM EDT AC Immune Announces Strategic Acquisition of Industry-leading Parkinson's Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH Benzinga

Jul 25, 2021

10:05AM EDT The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More Benzinga

Jun 25, 2021

08:39AM EDT AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that AC Immune held its Annual General Meeting per Swiss law. Shareholders cast their votes through the independent proxy appointed by the shareholders. GlobeNewswire Inc

Jun 2, 2021

08:20AM EDT The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements Benzinga

07:34AM EDT AC Immune Stock Jumps After Alzheimer's Disease Vaccine Candidate Confirms Favorable Safety, Tolerability Profile Benzinga

07:06AM EDT AC Immune Provides Update on Alzheimer's Disease Vaccine Candidates Targeting Pathological Amyloid-Beta Benzinga

07:00AM EDT Optimized vaccine candidate generates enhanced polyclonal antibody response against pyroglutamate Abeta in non-human primates GlobeNewswire Inc

May 20, 2021

07:00AM EDT AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will participate in the UBS Global Healthcare Virtual Conference and the Jefferies Virtual Healthcare Conference, taking place May 24-26, 2021 and June 1-4, 2021, respectively. GlobeNewswire Inc

May 17, 2021

09:55AM EDT AC Immune Provides Update On Alzheimer's Disease Vaccine Candidate Benzinga

07:14AM EDT AC Immune Announces Expansion of Phase 1b/2a phospho-Tau Alzheimer's Vaccine Trial and Provides a Program Update Benzinga

07:00AM EDT Previous interim results showing strong safety and potent immunogenicity support trial expansion and advancement of ACI-35.030 into Phase 2b/3 GlobeNewswire Inc

Apr 28, 2021

07:22AM EDT AC Immune Q1 EPS $(0.23) Down From $(0.11) YoY, Sales $12.28M Down From $12.92M YoY Benzinga

07:00AM EDT AC Immune Reports First Quarter 2021 Financial GlobeNewswire Inc

Apr 1, 2021

09:37AM EDT AC Immune US Patent & Trademark Office Abstract For Co.'s 'ANTI-ABETA THERAPEUTIC VACCINES' Benzinga

Mar 31, 2021

04:30PM EDT Dr. Colowick has more than 20 years of experience in large and emerging biotech companies GlobeNewswire Inc

07:00AM EDT AC Immune Hosts Investor Webinar Highlighting the Power of its GlobeNewswire Inc

Mar 26, 2021

07:00AM EDT Therapeutic and diagnostic Morphomers enable AC Immunes unique precision medicine approach for neurodegenerative diseases GlobeNewswire Inc

Mar 24, 2021

06:37AM EDT HC Wainwright & Co. Maintains Buy on AC Immune, Raises Price Target to $16 Benzinga

Mar 23, 2021

08:18AM EDT The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO Benzinga

08:01AM EDT Recap: AC Immune Q4 Earnings Benzinga

07:00AM EDT -- Anti-pTau Alzheimers vaccine delivers potent immunogenicity in ongoing Phase 1b/2a study, supporting further development into Phase 2/3 GlobeNewswire Inc

Mar 16, 2021

08:17AM EDT The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study Benzinga

07:07AM EDT AC Immune Highlights Presentation Of Clinical Results In Down Syndrome Benzinga

07:00AM EDT Topline ACI-24 Phase 1b immunogenicity and safety results reported today at a global Down syndrome symposium GlobeNewswire Inc

Mar 9, 2021

07:00AM EST Four presentations at AD/PD2021 feature latest findings from wholly owned therapeutic and diagnostic programs targeting pathological forms of alpha-synuclein and TDP-43 GlobeNewswire Inc

Feb 24, 2021

07:15AM EST AC Immune To Present New Data From Alpha-Synuclein And TDP-43 Programs At AD/PD 2021 Virtual Conference Benzinga

07:00AM EST AC Immune to Present New Data from Alpha-Synuclein and TDP-43 GlobeNewswire Inc

Feb 17, 2021

07:10AM EST AC Immune To Highlight Alzheimer's Vaccine At SVB Leerink 10th Annual Global Healthcare Conference Feb. 24, 11:2011:50 am ET Benzinga

07:00AM EST AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will participate in the upcoming SVB Leerink 10th Annual Global Healthcare Conference, taking place virtually on February 2226, 2021. GlobeNewswire Inc

Feb 11, 2021

11:26AM EST Mid-Morning Market Update: RCM Technologies Shares Spike Higher, Even As Walt Disney Prepares to Announce Q1 Results Benzinga

10:12AM EST Shares of AC Immune SA (ACIU) are currently gaining 35% on Thursday morning after the Switzerland-based clinical-stage biopharmaceutical company announced positive interim results from ongoing mid-stage trial in older patients with early Alzheimer's disease. RTTNews

07:00AM EST Interim results of ACI-35.030 vaccination show high titers of antigen-specific antibodies at potentially therapeutic levels in 100% of older patients with early Alzheimers disease GlobeNewswire Inc

Feb 8, 2021

07:18AM EST AC Immune Initiates Clinical Study Of First-in-class Diagnostic For Parkinson's Disease RTTNews

07:00AM EST AC Immune Initiates Clinical Study of GlobeNewswire Inc

Jan 29, 2021

07:07AM EST AC Immune Reports Progress For Therapeutic Programs Targeting NLRP3 Inflammasome Pathway Benzinga

07:00AM EST Highly potent in vivo anti-inflammatory activity demonstrated for novel small molecule NLRP3 inhibitors GlobeNewswire Inc

Dec 15, 2020

08:03AM EST AC Immune Reports Competitive Target ALS Foundation Grant To Accelerate Development of Proprietary Phosphorylated TDP-43 Immuno-Assay Benzinga

08:00AM EST Grant provides USD 600,000 in funding to support a world-class collaboration between ACImmune and Massachusetts General Hospital GlobeNewswire Inc

Nov 20, 2020

08:40AM EST Prof. June is a world authority on immune tolerance and adoptive immunotherapy GlobeNewswire Inc

Nov 18, 2020

07:00AM EST Prof. Streffer is anestablishedauthority on neuroscience and biomarker modalities GlobeNewswire Inc

Nov 13, 2020

07:40AM EST The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations Benzinga

07:27AM EST AC Immune: Q3 Earnings Insights Benzinga

07:24AM EST AC Immune Q3 Net Loss After Taxes CHF 19.0 Mln Vs Net Income CHF 18.2 Mln Last Year RTTNews

07:02AM EST AC Immune Q3 EPS $(0.26) Down From $0.25 YoY, Sales $1.12M Down From $33.74M YoY Benzinga

07:00AM EST AC Immune Reports Q3 2020 Financial Results and Provides Business GlobeNewswire Inc

Nov 12, 2020

07:00AM EST AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will participate in a fireside chat during the upcoming Jefferies Virtual London Healthcare Conference. GlobeNewswire Inc

Nov 9, 2020

04:00AM EST AC Immune and WuXi Biologics Strengthen Strategic Partnership to GlobeNewswire Inc

Oct 9, 2020

08:25AM EDT Competitive EU Grants Supports Collaboration To Accelerate Development Of AC Immune's First-In-Class TDP-43 Diagnostic Agent Benzinga

08:25AM EDT Grant from theEU Joint Programme Neurodegenerative Disease Research (JPND) provides 1.45M in funding for the program GlobeNewswire Inc

Sep 23, 2020

02:57PM EDT Mid-Afternoon Market Update: Dow Tumbles 400 Points; JinkoSolar Shares Jump Benzinga

12:20PM EDT Mid-Day Market Update: Gold Falls 2%; SPI Energy Shares Spike Higher Benzinga

11:29AM EDT Mid-Morning Market Update: Markets Mixed; General Mills Beats Q1 Estimates Benzinga

10:35AM EDT Shares of AC Immune SA (ACIU) are losing over 40% on Wednesday morning after its mid-stage study evaluating Semorinemab in early alzheimer's disease failed to meet primary goals. RTTNews

10:11AM EDT Mid-Morning Market Update: Markets Mixed; General Mills Beats Q1 Estimates Benzinga

07:03AM EDT AC Immune Reports Genentech Disclosed That The Anti-Tau Antibody Did Not Meet The Co-primary Efficacy Endpoint Or Two Secondary Endpoints In The Tauriel Study; The Primary Safety Endpoint Was Met Benzinga

07:00AM EDT Genentech disclosed that the anti-Tau antibody did not meet the co-primary efficacy endpoint or two secondary endpoints in the TAURIEL study; the primary safety endpoint was met GlobeNewswire Inc

Sep 11, 2020

07:00AM EDT AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will showcase recent progress in its clinical programs targeting Tau for neurodegenerative diseases at the upcoming H.C. Wainwright 22nd Annual Global Investment Conference. GlobeNewswire Inc

Sep 8, 2020

05:15PM EDT AC Immune SA Announces Co. Entered Into An Open Market Sale Agreement Of Up To $80M Benzinga

Aug 5, 2020

08:16AM EDT AC Immune Q2 EPS CHF(0.22) Up From CHF(0.23) YoY, Sales CHF1.278M Benzinga

07:00AM EDT AC Immune Reports Q2 2020 Financial Results and Provides Business GlobeNewswire Inc

Aug 3, 2020

07:11AM EDT AC Immune Initiates IND-Enabling Studies For First-In-Class Antibody Targeting TDP-43 To Treat Neurodegeneration Benzinga

07:00AM EDT AC Immune Initiates IND-Enabling Studies for First-in-Class GlobeNewswire Inc

Jul 30, 2020

07:58AM EDT AC Immune Announces It Is One Of The Winners Of Ken Griffin Alpha-Synuclein Imaging Competition From The Michael J. Fox Foundation For Parkinson's Research And Is Eligible To Receive $3.2M With Its Partner Benzinga

07:55AM EDT AC Immune Wins Prestigious Award to Develop a GlobeNewswire Inc

Jul 28, 2020

07:20AM EDT UPDATE: AC Immune Reports PET Tracer Detects Pathological Alpha-Synclein With Improved Signal-To-Noise Ratio Benzinga

07:13AM EDT AC Immune Highlights Presentation Of Data For Alpha-Synuclein Positron Emission Tomography Benzinga

07:00AM EDT Next-generation PET tracer detects pathological alpha-synuclein with improved signal-to-noise ratio GlobeNewswire Inc

Jul 23, 2020

07:00AM EDT AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, with a broad pipeline focused on neurodegenerative diseases, today announced two oral presentations will be delivered at this years Alzheimers Association International Conference (AAIC) which takes place virtually July 27 31, 2020. GlobeNewswire Inc

Jul 17, 2020

05:08AM EDT 64 Biggest Movers From Yesterday Benzinga

Jul 16, 2020

04:45PM EDT 04:45 Thursday, July 16, 2020 RTTNews

10:14AM EDT Shares of Switzerland-based AC Immune SA (ACIU) are surging more than 68 percent or $4.93 in Thursday's morning trade at $12.12, after earlier touching a new 52-week high of $13.00. RTTNews

10:13AM EDT Mid-Morning Market Update: Markets Open Lower; Bank of America Earnings Top Views Benzinga

09:55AM EDT Morning Market Stats in 5 Minutes Benzinga

08:05AM EDT Shares of AC Immune SA (ACIU) are surging over 82% in pre-market today, after the company announced the initiation of the second highest dosing group its Phase 1b/2a clinical trial evaluating ACI-35.030 for the treatment of Alzheimer's disease (AD). RTTNews

07:04AM EDT AC Immune Advances Phospho-Tau Alzheimer's Vaccine In Phase 1b/2a Study Benzinga

07:00AM EDT Interim data confirm the promising safety, tolerability and Tau-specific immunogenicity observed in the previous clinical study GlobeNewswire Inc

document.getElementById("bjpcMj").onerror = function(){this.style.display='none';}; .dark-mode .nnXhlx{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .nnXhlx{ color: #333333; background-color: white; border: 2px solid #333333; }ACIUAC Immune SAstock NASDAQ

ACIU
AC Immune SA
stock NASDAQ